340B Drug Pricing Program
AHA, 340B hospitals and stakeholders voice concerns with two pieces of legislation that were recently passed out of the House Energy and Commerce Committee’s Health Subcommittee.
AHA, others voice strong opposition to 340B proposals being considered by House E&C Committee
AHA statement on legislative proposals that are to be considered before the Energy and Commerce Committee on May 24.
The House Energy and Commerce Subcommittee on Health yesterday advanced a series of health care bills, and voted to pass and send to the full committee a bill that would impose additional reporting requirements on hospitals that participate in the 340B Drug Pricing Program.
The House Energy and Commerce Subcommittee on Health May 17 considered a series of health care bills, including a number focused on provisions that would affect hospitals and health systems.
AHA shares hospital field’s comments on legislative proposals that are to be considered before the Energy & Commerce Health Subcommittee on May 17.
Several House and Senate committees will hold hearings this week on a variety of issues that affect hospitals and health systems.
The AHA strongly opposes legislation that would lead to additional site-neutral payment cuts and threaten access to patient care, Ashley Thompson, AHA senior vice president of public policy analysis and development, told the House Energy and Commerce Subcommittee on Health today during a hearing…
The health care workforce, 340B Drug Pricing Program and end of the COVID-19 public health emergency are at the forefront of AHA’s discussions with lawmakers, said Stacey Hughes, AHA's executive vice president of government relations and public policy, during the annual meeting opening plenary.
Several House subcommittees April 26 will hold hearings on a variety of issues that affect hospitals and health systems, including transparency, site-neutral payment policies, tax-exempt status, workforce shortages and the Provider Relief Fund.